Basic Information
RNALocate ID: | RLID:11001465 |
RNA Symbol: | hsa-miR-203a-3p |
Localization: | Microvesicle |
RNA Information
RNA Name: | hsa-miR-203a-3p |
RNA ID: | miRBase:MIMAT0000264 |
RNA Category: | miRNA |
Species: | Homo sapiens |
Localization Information
PubMed ID: | 25330373 |
Tissue/Cell Line: | Colon cancer cell line (LIM1863) |
Method: | qRT-PCR|RNA sequencing |
Description: | To assess whether some miRNAs are specifically sorted into EVs we conducted a miRNA-enrichment analysis for A33-Exos, EpCAM-Exos and sMVs. MiRNAs with <2 fold changes relative to CL miRNAs were filtered out, yielding 63 miRNAs for comparison (Table 2). Data are collected from Table 2. |
Other Subcellular Localization
RNALocate ID | Localization | Tissue/Cell line | PubMed ID |
RLID:11001461 | Exosome | Brain tissue | 23382797 |
RLID:11001462 | Exosome | Plasma | 23663360 |
RLID:11001463 | Exosome | Colon cancer cell line (LIM1863) | 25330373 |
RLID:11001464 | Microvesicle | Follicular fluid | 23666971 |
RLID-D:11000055 | Exosome | Blood|Breast tissue|Colon tissue|Seminal fluid|Tongue tissue | |
RLID-D:11000325 | Microvesicle | Breast cell line|Colon cancer cell line (LIM1863)|Urine |
ncRNA Disease Information
Resource | RNA Symbol | Disease | Link |
MNDR | hsa-miR-203a-3p | Multiple sclerosis chronic progressive | MNDR-E-MI-26706 |
MNDR | hsa-miR-203a-3p | Oral squamous cell carcinoma | MNDR-E-MI-26707 |
MNDR | hsa-miR-203a-3p | Medulloblastoma | MNDR-E-MI-26708 |
MNDR | hsa-miR-203a-3p | Small intestinal neuroendocrine tumor | MNDR-E-MI-26709 |
MNDR | hsa-miR-203a-3p | High-grade serous ovarian carcinoma | MNDR-E-MI-26710 |
MNDR | hsa-miR-203a-3p | Ovarian clear cell carcinoma | MNDR-E-MI-26711 |
MNDR | hsa-miR-203a-3p | Uterine corpus endometrial carcinoma | MNDR-E-MI-26712 |
MNDR | hsa-miR-203a-3p | Lymphoma | MNDR-E-MI-26713 |
MNDR | hsa-miR-203a-3p | Cutaneous t cell lymphoma | MNDR-E-MI-26714 |
MNDR | hsa-miR-203a-3p | Estrogen-receptor positive breast cancer | MNDR-E-MI-26715 |
MNDR | hsa-miR-203a-3p | Estrogen-receptor negative breast cancer | MNDR-E-MI-26716 |
MNDR | hsa-miR-203a-3p | Progesterone-receptor positive breast cancer | MNDR-E-MI-26717 |
MNDR | hsa-miR-203a-3p | Progesterone-receptor negative breast cancer | MNDR-E-MI-26718 |
MNDR | hsa-miR-203a-3p | Her2-receptor positive breast cancer | MNDR-E-MI-26719 |
MNDR | hsa-miR-203a-3p | Breast cancer luminal | MNDR-E-MI-26720 |
MNDR | hsa-miR-203a-3p | Bone disease | MNDR-E-MI-26721 |
MNDR | hsa-miR-203a-3p | Precursor cell lymphoblastic leukemia-lymphoma | MNDR-E-MI-26722 |
MNDR | hsa-miR-203a-3p | Neurofibromatosis 1 | MNDR-E-MI-26723 |
MNDR | hsa-miR-203a-3p | Small intestine cancer | MNDR-E-MI-26724 |
MNDR | hsa-miR-203a-3p | Prostate cancer | MNDR-E-MI-26725 |
MNDR | hsa-miR-203a-3p | Gastric cancer | MNDR-E-MI-26726 |
MNDR | hsa-miR-203a-3p | Alzheimer disease | MNDR-E-MI-26727 |
MNDR | hsa-miR-203a-3p | Urinary bladder cancer | MNDR-E-MI-26728 |
MNDR | hsa-miR-203a-3p | Dysautonomia familial | MNDR-E-MI-26729 |
MNDR | hsa-miR-203a-3p | Polycystic ovary syndrome | MNDR-E-MI-26730 |
MNDR | hsa-miR-203a-3p | Cardiovascular disease | MNDR-E-MI-26731 |
MNDR | hsa-miR-203a-3p | Uterine fibroid | MNDR-E-MI-26732 |
MNDR | hsa-miR-203a-3p | Lung cancer | MNDR-E-MI-26733 |
MNDR | hsa-miR-203a-3p | Endometrial cancer | MNDR-E-MI-26734 |
MNDR | hsa-miR-203a-3p | Parkinson disease | MNDR-E-MI-26735 |
MNDR | hsa-miR-203a-3p | Basal-like breast cancer | MNDR-E-MI-26736 |
MNDR | hsa-miR-203a-3p | Thyroid cancer | MNDR-E-MI-26737 |
MNDR | hsa-miR-203a-3p | Malignant mesothelioma | MNDR-E-MI-26738 |
MNDR | hsa-miR-203a-3p | Pancreatic cancer | MNDR-E-MI-26739 |
MNDR | hsa-miR-203a-3p | Melanoma | MNDR-E-MI-26740 |
MNDR | hsa-miR-203a-3p | Rectum adenocarcinoma | MNDR-E-MI-26741 |
MNDR | hsa-miR-203a-3p | Nephroblastoma | MNDR-E-MI-26742 |
MNDR | hsa-miR-203a-3p | Colon cancer | MNDR-E-MI-26743 |
MNDR | hsa-miR-203a-3p | Essential thrombocythemia | MNDR-E-MI-26744 |
MNDR | hsa-miR-203a-3p | Ischemic attack transient | MNDR-E-MI-26745 |
MNDR | hsa-miR-203a-3p | Colon adenocarcinoma | MNDR-E-MI-26746 |
MNDR | hsa-miR-203a-3p | Multiple sclerosis relapsing-remitting | MNDR-E-MI-26747 |
MNDR | hsa-miR-203a-3p | Ovarian cancer | MNDR-E-MI-26748 |
MNDR | hsa-miR-203a-3p | Prostate adenocarcinoma | MNDR-E-MI-26749 |
MNDR | hsa-miR-203a-3p | Carcinoma ductal breast | MNDR-E-MI-26750 |
MNDR | hsa-miR-203a-3p | Glioblastoma | MNDR-E-MI-26751 |
MNDR | hsa-miR-203a-3p | Astrocytoma | MNDR-E-MI-26752 |
MNDR | hsa-miR-203a-3p | Glioma | MNDR-E-MI-26753 |
MNDR | hsa-miR-203a-3p | Chronic obstructive pulmonary disease | MNDR-E-MI-26754 |
MNDR | hsa-miR-203a-3p | Atopic dermatitis | MNDR-E-MI-26755 |
MNDR | hsa-miR-203a-3p | Epilepsy temporal lobe | MNDR-E-MI-26756 |
MNDR | hsa-miR-203a-3p | Osteosarcoma | MNDR-E-MI-26757 |
MNDR | hsa-miR-203a-3p | Breast carcinoma | MNDR-E-MI-26758 |
MNDR | hsa-miR-203a-3p | Pancreatic ductal adenocarcinoma | MNDR-E-MI-26759 |
MNDR | hsa-miR-203a-3p | Uterine cancer | MNDR-E-MI-26760 |
MNDR | hsa-miR-203a-3p | Skin disease | MNDR-E-MI-26761 |
MNDR | hsa-miR-203a-3p | Cervical adenocarcinoma | MNDR-E-MI-26762 |
MNDR | hsa-miR-203a-3p | Gastric adenocarcinoma | MNDR-E-MI-26763 |
MNDR | hsa-miR-203a-3p | Cervical squamous cell carcinoma | MNDR-E-MI-26764 |
MNDR | hsa-miR-203a-3p | Lung squamous cell carcinoma | MNDR-E-MI-26765 |
MNDR | hsa-miR-203a-3p | Carcinoma lung non-small-cell | MNDR-E-MI-26766 |
MNDR | hsa-miR-203a-3p | Lung adenocarcinoma | MNDR-E-MI-26767 |
MNDR | hsa-miR-203a-3p | Thyroid carcinoma | MNDR-E-MI-26768 |
MNDR | hsa-miR-203a-3p | Ovarian carcinoma | MNDR-E-MI-26769 |
MNDR | hsa-miR-203a-3p | Bladder urothelial carcinoma | MNDR-E-MI-26770 |
MNDR | hsa-miR-203a-3p | Pancreatic adenocarcinoma | MNDR-E-MI-26771 |
MNDR | hsa-miR-203a-3p | Carcinoma renal cell | MNDR-E-MI-26772 |
MNDR | hsa-miR-203a-3p | Kidney renal papillary cell carcinoma | MNDR-E-MI-26773 |
MNDR | hsa-miR-203a-3p | Renal clear cell carcinoma | MNDR-E-MI-26774 |
MNDR | hsa-miR-203a-3p | Esophageal cancer | MNDR-E-MI-26775 |
MNDR | hsa-miR-203a-3p | Lung small cell carcinoma | MNDR-E-MI-26776 |
MNDR | hsa-miR-203a-3p | Head and neck squamous cell carcinoma | MNDR-E-MI-26777 |
MNDR | hsa-miR-203a-3p | Testicular germ cell cancer | MNDR-E-MI-26778 |
MNDR | hsa-miR-203a-3p | Oral submucous fibrosis | MNDR-E-MI-26779 |
MNDR | hsa-miR-203a-3p | Breast invasive carcinoma | MNDR-E-MI-26780 |
MNDR | hsa-miR-203a-3p | Hepatocellular carcinoma | MNDR-E-MI-26781 |
MNDR | hsa-miR-203a-3p | B-cell lymphoma | MNDR-E-MI-26782 |
MNDR | hsa-miR-203a-3p | Rheumatoid arthritis | MNDR-E-MI-26783 |
MNDR | hsa-miR-203a-3p | Neuroblastoma | MNDR-E-MI-26784 |
MNDR | hsa-miR-203a-3p | Barrett's adenocarcinoma | MNDR-E-MI-26785 |
MNDR | hsa-miR-203a-3p | Gastroesophageal reflux disease | MNDR-E-MI-26786 |
MNDR | hsa-miR-203a-3p | Chronic myeloid leukemia | MNDR-E-MI-26787 |
MNDR | hsa-miR-203a-3p | Ulcerative colitis | MNDR-E-MI-26788 |
MNDR | hsa-miR-203a-3p | Tonsil cancer | MNDR-E-MI-26789 |
MNDR | hsa-miR-203a-3p | Psoriasis | MNDR-E-MI-26790 |
MNDR | hsa-miR-203a-3p | Skin cutaneous melanoma | MNDR-E-MI-26791 |
MNDR | hsa-miR-203a-3p | Skin melanoma | MNDR-E-MI-26792 |
MNDR | hsa-miR-203a-3p | Acute myeloid leukemia | MNDR-E-MI-26793 |
MNDR | hsa-miR-203a-3p | Colorectal cancer | MNDR-E-MI-26794 |
MNDR | hsa-miR-203a-3p | Nasopharyngeal carcinoma | MNDR-E-MI-26795 |
MNDR | hsa-miR-203a-3p | Nasopharynx carcinoma | MNDR-E-MI-26796 |
MNDR | hsa-miR-203a-3p | Multiple myeloma | MNDR-E-MI-26797 |
MNDR | hsa-miR-203a-3p | Uterine cervical neoplasms | MNDR-E-MI-26798 |
MNDR | hsa-miR-203a-3p | Ependymoma | MNDR-E-MI-26799 |
MNDR | hsa-miR-203a-3p | Nasopharyngeal cancer | MNDR-E-MI-26800 |
MNDR | hsa-miR-203a-3p | Nerve degeneration | MNDR-E-MI-26801 |
MNDR | hsa-miR-203a-3p | Prostatic neoplasms | MNDR-E-MI-26802 |
MNDR | hsa-miR-203a-3p | Non-alcoholic fatty liver disease | MNDR-E-MI-26803 |
MNDR | hsa-miR-203a-3p | Barrett's carcinogenesis | MNDR-E-MI-26804 |
MNDR | hsa-miR-203a-3p | Duke C | MNDR-E-MI-26805 |
RNA Interaction Information
Resource | RNA Symbol | Species | Link | RNALocate ID |
RNAInter | ABCE1 | Homo sapiens | RR00024333 |
TOP